NetScientific plc (GB:NSCI) has released an update.
NetScientific plc has announced that its portfolio company, PDS Biotechnology, has achieved promising results in its Phase 2 VERSATILE-002 trial for treating HPV16-positive head and neck cancer. With a median overall survival rate of 30 months, the study’s outcomes far surpass those of existing immune checkpoint inhibitors. PDS Biotech is planning to initiate a Phase 3 trial in 2024, aiming to further evaluate its innovative combination therapy, which has demonstrated potential in both efficacy and tolerability.
For further insights into GB:NSCI stock, check out TipRanks’ Stock Analysis page.
